Navigation Links
Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
Date:3/30/2009

LA JOLLA, Calif., March 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the United States District Court of the Southern District of New York dismissed proceedings filed in February 2005 by former stockholders of Axonyx Inc. ("Axonyx") against Axonyx and several of Axonyx's former directors and officers. TorreyPines acquired Axonyx Inc. in 2006. The plaintiffs alleged that the defendants made misleading statements related to Phase III clinical trials of Axonyx's drug candidate, phenserine. The complaint was dismissed in its entirety. In January 2009 a related outstanding derivative action against Axonyx was discontinued by the New York Supreme Court.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:                                Investor contact:
    Paul Schneider                                  Rhonda Chiger
    TorreyPines Therapeutics, Inc.                  Rx Communications Group
    858-623-5665 x 125                              (917) 322-2569
    pschneider@TPTXinc.com                          rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ev3 and FoxHollow Announce Date for Special Meeting of FoxHollow Stockholders to Vote on Proposed Merger
2. Micrus Endovascular to Webcast Fiscal 2007 Annual Meeting of Stockholders
3. Kyphon Stockholders Approve Merger with Medtronic
4. Paramount Stockholders Approve Acquisition of Chem Rx
5. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
8. VaxGen Addresses MPM Claims in Letter to Stockholders
9. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
10. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
11. Special Stockholders Meeting to Elect Directors Set for March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... expansion to their comprehensive training and support program, Sonalink™ remote monitoring. The inaugural ... procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Cenna ... agents for the treatment of Alzheimer’s disease, announced today it has been selected to ... 18th at the Breakers in Palm Beach, Florida. The purpose of the Forum ...
(Date:2/9/2016)... ... 2016 , ... With a presidential election in November and the future of ... together over 500 top healthcare leaders for a night and day of debates and ... MBA students of the University of Pennsylvania’s Wharton School, will be held February 18 ...
Breaking Biology Technology:
(Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Facial Recognition Market ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ... Market 2016-2020" report to their offering. ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ...
(Date:2/3/2016)... 3, 2016 Vigilant Solutions announces today that ... Missouri solved two recent hit-and-run ... data from Vigilant Solutions. Brian Wenberg ... the victim was walking out of a convenience store and witnessed an elderly ... his vehicle, striking his vehicle and leaving the scene.  ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):